Alzheimer's & Cognition
News
FDA okays first tau radiotracer to aid Alzheimer’s disease diagnosis
This is the first drug approved for imaging tau pathology, one of the two neuropathologic hallmarks of Alzheimer’s disease.
Conference Coverage
Mixed results for aducanumab in two phase 3 trials for Alzheimer’s disease
One of two “identical studies” assessing a novel treatment in development for Alzheimer’s disease reports significant efficacy, while the other...
Conference Coverage
COVID-19: Psychiatrists assess geriatric harm from social distancing
“Certainly the appalling number of deaths in nursing homes is the No. 1 horror of the pandemic.”
Commentary
Neuropsychiatric manifestations of COVID-19
When assessing altered mental status, consider COVID-19 in your differential diagnosis.
Literature Review
Framingham risk score may also predict cognitive decline
“In the absence of effective treatments for dementia, we need to monitor and control cardiovascular risk burden as a way to maintain patient’s...
Literature Review
Blood pressure lowering lessens risk of dementia, cognitive decline
“These findings have the potential to inform public health strategies to reduce the burden of dementia globally.”
Conference Coverage
Incidental finding on brain MRI seen in 5% of older patients
Knowing the expected prevalence of such incidental findings in the older general population is “extremely useful” for both researchers and...
Conference Coverage
Diastolic dysfunction is a common risk factor for cognitive decline
Proposed mechanisms for cognitive decline in patients with systolic dysfunction include low cardiac output, embolic infarctions, and hypoxic...
From the Journals
FOURIER: Evolocumab follow-up shows no cognitive adverse effects
A cognition survey of more than 22,000 FOURIER patients showed no compromise linked to evolocumab or sharply cut LDL-C levels.
Conference Coverage
A healthy heart in youth protects the brain later on
“What is good for the heart is also good for the brain.”
Conference Coverage
New gene variants linked to tau deposits in Alzheimer’s disease
New genetic insights may better predict who may become symptomatic from the disease and help develop targets for treatment.